Published in FASEB J on August 01, 2002
Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine (2008) 4.59
Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater (2009) 2.87
Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn (2009) 2.35
Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev (2007) 1.92
Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology (2006) 1.92
The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials (2009) 1.82
Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Mol Pharm (2009) 1.61
NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond) (2009) 1.55
Retracted Rapamycin-loaded nanoparticles for inhibition of neointimal hyperplasia in experimental vein grafts. J Cardiothorac Surg (2011) 1.42
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci (2007) 1.41
Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm (2008) 1.39
Drug transport to brain with targeted nanoparticles. NeuroRx (2005) 1.37
Nanoparticles for applications in cellular imaging. Nanoscale Res Lett (2007) 1.34
Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS One (2009) 1.31
ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur J Pharm Sci (2009) 1.29
In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev (2014) 1.28
Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine (2011) 1.26
Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnology (2011) 1.20
Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. Nucleic Acid Ther (2012) 1.19
Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials (2008) 1.18
Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale (2010) 1.15
Unveiling the mechanism of uptake and sub-cellular distribution of cerium oxide nanoparticles. Mol Biosyst (2010) 1.15
Advanced materials and processing for drug delivery: the past and the future. Adv Drug Deliv Rev (2012) 1.14
Quantification of the force of nanoparticle-cell membrane interactions and its influence on intracellular trafficking of nanoparticles. Biomaterials (2008) 1.14
Nanoparticle-based endodontic antimicrobial photodynamic therapy. J Endod (2009) 1.12
Exploiting lipid raft transport with membrane targeted nanoparticles: a strategy for cytosolic drug delivery. Biomaterials (2008) 1.12
Nano-vectors for efficient liver specific gene transfer. Int J Nanomedicine (2008) 1.11
Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem (2009) 1.11
Nanovehicular intracellular delivery systems. J Pharm Sci (2008) 1.10
Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects. Nano Today (2014) 1.09
Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes (2009) 1.08
Ex vivo red blood cell hemolysis assay for the evaluation of pH-responsive endosomolytic agents for cytosolic delivery of biomacromolecular drugs. J Vis Exp (2013) 1.08
Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation. Bioconjug Chem (2009) 1.06
Acidic nanoparticles are trafficked to lysosomes and restore an acidic lysosomal pH and degradative function to compromised ARPE-19 cells. PLoS One (2012) 1.05
Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today (2012) 1.04
Poloxamer 407/TPGS mixed micelles for delivery of gambogic acid to breast and multidrug-resistant cancer. Int J Nanomedicine (2012) 1.02
Dynamics and mechanisms of quantum dot nanoparticle cellular uptake. J Nanobiotechnology (2010) 1.02
PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Int J Nanomedicine (2012) 1.01
Unambiguous observation of shape effects on cellular fate of nanoparticles. Sci Rep (2014) 1.00
Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy. Bioconjug Chem (2010) 1.00
Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms. Nanomedicine (2010) 1.00
Engineering cells with intracellular agent-loaded microparticles to control cell phenotype. Nat Protoc (2014) 0.99
Quantum dot-fluorescent protein FRET probes for sensing intracellular pH. ACS Nano (2012) 0.98
Nanodelivery in airway diseases: challenges and therapeutic applications. Nanomedicine (2009) 0.97
Particle size and temperature effect on the physical stability of PLGA nanospheres and microspheres containing Bodipy. AAPS PharmSciTech (2004) 0.96
Kinetically controlled cellular interactions of polymer-polymer and polymer-liposome nanohybrid systems. Bioconjug Chem (2011) 0.96
Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. AIDS Res Hum Retroviruses (2013) 0.95
Drug-loaded nanoparticle systems and adult stem cells: a potential marriage for the treatment of malignant glioma? Oncotarget (2013) 0.93
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv Drug Deliv Rev (2013) 0.92
A phosphate-dependent shift in redox state of cerium oxide nanoparticles and its effects on catalytic properties. Biomaterials (2011) 0.92
Nanomedicine as an emerging approach against intracellular pathogens. Int J Nanomedicine (2011) 0.91
Biodegradable nanoparticles sequentially decorated with Polyethyleneimine and Hyaluronan for the targeted delivery of docetaxel to airway cancer cells. J Nanobiotechnology (2015) 0.91
In vitro interaction of colloidal nanoparticles with mammalian cells: What have we learned thus far? Beilstein J Nanotechnol (2014) 0.90
Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders. Drug Deliv Transl Res (2012) 0.89
Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells. Mol Vis (2011) 0.89
Multifunctional nanoparticles for doxycycline delivery towards localized elastic matrix stabilization and regenerative repair. Acta Biomater (2013) 0.87
Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity. Front Oncol (2012) 0.87
Nanoparticulate systems for polynucleotide delivery. Int J Nanomedicine (2007) 0.87
Inhibition of tumor angiogenesis and growth by nanoparticle-mediated p53 gene therapy in mice. Cancer Gene Ther (2012) 0.87
Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy. Int J Nanomedicine (2014) 0.87
Activation of caspase-dependent apoptosis by intracellular delivery of Cytochrome c-based nanoparticles. J Nanobiotechnology (2014) 0.86
Intracellular uptake and trafficking of difluoroboron dibenzoylmethane-polylactide nanoparticles in HeLa cells. ACS Nano (2010) 0.86
Drug delivery to the posterior segment of the eye for pharmacologic therapy. Expert Rev Ophthalmol (2010) 0.85
Studies of the cellular uptake of hydrogel nanospheres and microspheres by phagocytes, vascular endothelial cells, and smooth muscle cells. J Biomed Mater Res A (2009) 0.85
Safety assessment of oral photodynamic therapy in rats. Lasers Med Sci (2012) 0.85
Polymeric vectors for ocular gene delivery. Ther Deliv (2011) 0.84
Nanotechnology-based drug delivery systems for treatment of oral cancer: a review. Int J Nanomedicine (2014) 0.84
Nanoparticle-mediated catalase delivery protects human neurons from oxidative stress. Cell Death Dis (2013) 0.84
The potential of nanomedicine therapies to treat neovascular disease in the retina. J Angiogenes Res (2010) 0.84
Luminescent silica nanobeads: characterization and evaluation as efficient cytoplasmatic transporters for T-lymphocytes. J Am Chem Soc (2007) 0.84
Nanoparticle-mediated p53 gene therapy for tumor inhibition. Drug Deliv Transl Res (2011) 0.84
Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) and poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol) blend for prostate cancer treatment. Mol Pharm (2013) 0.83
A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials (2013) 0.83
Formulation of polylactide-co-glycolic acid nanospheres for encapsulation and sustained release of poly(ethylene imine)-poly(ethylene glycol) copolymers complexed to oligonucleotides. J Nanobiotechnology (2009) 0.83
Preparation and Characterization of Cationic PLA-PEG Nanoparticles for Delivery of Plasmid DNA. Nanoscale Res Lett (2009) 0.82
Nanoparticle-mediated expression of a Wnt pathway inhibitor ameliorates ocular neovascularization. Arterioscler Thromb Vasc Biol (2015) 0.82
Novel polymeric nanoparticles for intracellular delivery of peptide Cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9. Cancer Res (2014) 0.82
Cationic surface modification of PLG nanoparticles offers sustained gene delivery to pulmonary epithelial cells. J Pharm Sci (2010) 0.82
Photodynamic effects of methylene blue-loaded polymeric nanoparticles on dental plaque bacteria. Lasers Surg Med (2011) 0.82
Interfacial activity assisted surface functionalization: a novel approach to incorporate maleimide functional groups and cRGD peptide on polymeric nanoparticles for targeted drug delivery. Mol Pharm (2010) 0.81
Composite polylactic-methacrylic Acid copolymer nanoparticles for the delivery of methotrexate. J Drug Deliv (2012) 0.81
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS One (2013) 0.81
Chitosan and glyceryl monooleate nanostructures containing gemcitabine: potential delivery system for pancreatic cancer treatment. AAPS PharmSciTech (2010) 0.81
Dawn of advanced molecular medicine: nanotechnological advancements in cancer imaging and therapy. Crit Rev Oncog (2014) 0.81
Self-assembled nanoparticles based on modified cationic dipeptides and DNA: novel systems for gene delivery. J Nanobiotechnology (2013) 0.81
Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles. PLoS One (2013) 0.81
Nanoparticle-based technologies for retinal gene therapy. Eur J Pharm Biopharm (2015) 0.81
A novel type of self-assembled nanoparticles as targeted gene carriers: an application for plasmid DNA and antimicroRNA oligonucleotide delivery. Int J Nanomedicine (2016) 0.80
AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects. Invest Ophthalmol Vis Sci (2011) 0.80
Synthesis and biological evaluation of a new polymeric conjugate and nanocarrier with osteotropic properties. J Funct Biomater (2012) 0.80
Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles. Biomaterials (2011) 0.80
Thermal and pH Sensitive Multifunctional Polymer Nanoparticles for Cancer Imaging and Therapy. RSC Adv (2014) 0.80
Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4. Int J Nanomedicine (2013) 0.80
Inhalation of silver nanomaterials--seeing the risks. Int J Mol Sci (2014) 0.80
Acid-Sensitive Sheddable PEGylated PLGA Nanoparticles Increase the Delivery of TNF-α siRNA in Chronic Inflammation Sites. Mol Ther Nucleic Acids (2016) 0.80
Gene delivery nanoparticles fabricated by supercritical fluid extraction of emulsions. Int J Pharm (2009) 0.79
Intracellular delivery of nanoparticles of an antiasthmatic drug. AAPS PharmSciTech (2008) 0.79
Effect of Aminated Mesoporous Bioactive Glass Nanoparticles on the Differentiation of Dental Pulp Stem Cells. PLoS One (2016) 0.79
Small Wonders-The Use of Nanoparticles for Delivering Antigen. Vaccines (Basel) (2015) 0.79
Enhanced Human Epidermal Growth Factor Receptor 2 Degradation in Breast Cancer Cells by Lysosome-Targeting Gold Nanoconstructs. ACS Nano (2015) 0.78
Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev (2003) 7.08
Nanotech approaches to drug delivery and imaging. Drug Discov Today (2003) 3.63
Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm (2005) 3.08
Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol Pharm (2008) 2.90
Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release (2002) 2.52
Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res (2003) 2.32
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev (2010) 2.23
Characterization of nanoparticle uptake by endothelial cells. Int J Pharm (2002) 2.13
3-D tumor model for in vitro evaluation of anticancer drugs. Mol Pharm (2008) 2.11
Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm (2002) 2.06
Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev (2007) 1.92
Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine (2011) 1.87
Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control Release (2003) 1.72
Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials (2008) 1.70
Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer (2004) 1.60
Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles. Int J Pharm (2003) 1.57
The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials (2010) 1.56
Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm (2005) 1.55
Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials (2009) 1.48
Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion. Cancer Lett (2013) 1.43
The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res (2004) 1.42
In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res (2003) 1.31
Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials (2010) 1.29
Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J Pharm Sci (2004) 1.28
TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials (2008) 1.28
Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. FASEB J (2009) 1.26
Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Clin Pharmacokinet (2006) 1.24
Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol Pharm (2004) 1.23
Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today (2010) 1.22
Magnetic resonance imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-bearing mice. Biomaterials (2009) 1.19
Critical determinants in PLGA/PLA nanoparticle-mediated gene expression. Pharm Res (2004) 1.18
Quantification of the force of nanoparticle-cell membrane interactions and its influence on intracellular trafficking of nanoparticles. Biomaterials (2008) 1.14
Targeted drug delivery in cancer therapy. Technol Cancer Res Treat (2005) 1.13
Retracted Enhanced in vitro antiproliferative effects of EpCAM antibody-functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells. Mol Vis (2011) 1.12
PEG-functionalized magnetic nanoparticles for drug delivery and magnetic resonance imaging applications. Pharm Res (2010) 1.11
Biophysical interactions with model lipid membranes: applications in drug discovery and drug delivery. Mol Pharm (2009) 1.11
Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur J Pharm Sci (2009) 1.10
Targeting intracellular targets. Curr Drug Deliv (2004) 1.07
Effect of molecular structure of cationic surfactants on biophysical interactions of surfactant-modified nanoparticles with a model membrane and cellular uptake. Langmuir (2009) 1.06
Polymeric nanoparticles for cancer therapy. J Drug Target (2008) 1.05
Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids. Mol Pharm (2010) 1.05
Targeting anti-HIV drugs to the CNS. Expert Opin Drug Deliv (2009) 1.05
Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. Mol Pharm (2005) 1.04
Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors. J Clin Invest (2012) 1.04
Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm (2011) 1.03
Optical imaging and magnetic field targeting of magnetic nanoparticles in tumors. ACS Nano (2010) 1.02
Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis. Mol Vis (2003) 1.00
Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomedicine (2011) 0.99
Inhibition of apoptosis through localized delivery of rapamycin-loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured artery. Circ Cardiovasc Interv (2008) 0.98
Oh the irony: Iron as a cancer cause or cure? Biomaterials (2011) 0.98
Tumor ablation and nanotechnology. Mol Pharm (2010) 0.98
Characterization of porous PLGA/PLA microparticles as a scaffold for three dimensional growth of breast cancer cells. Biomacromolecules (2005) 0.97
Retracted Enhanced antiproliferative activity of carboplatin-loaded chitosan-alginate nanoparticles in a retinoblastoma cell line. Acta Biomater (2010) 0.97
Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. Appl Biochem Biotechnol (2008) 0.95
Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv (2009) 0.93
Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer. Biomaterials (2010) 0.91
Receptor mediated tumor targeting: an emerging approach for cancer therapy. Curr Drug Deliv (2011) 0.91
Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles. Adv Drug Deliv Rev (2013) 0.90
Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur J Pharmacol (2011) 0.90
Polymeric nanoparticles for gene delivery. Expert Opin Drug Deliv (2006) 0.89
Biophysical characterization of nanoparticle-endothelial model cell membrane interactions. Mol Pharm (2008) 0.89
Advances in stroke therapy. Drug Deliv Transl Res (2011) 0.88
Sustained antibacterial activity of doxycycline-loaded poly(D,L-lactide-co-glycolide) and poly(epsilon-caprolactone) nanoparticles. Nanomedicine (Lond) (2009) 0.88
Relevance of biophysical interactions of nanoparticles with a model membrane in predicting cellular uptake: study with TAT peptide-conjugated nanoparticles. Mol Pharm (2009) 0.88
Curcumin-encapsulated MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy. Nanomedicine (Lond) (2010) 0.86
Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions. Mol Pharm (2012) 0.86
Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS One (2012) 0.86
Nanoparticles: cellular uptake and cytotoxicity. Adv Exp Med Biol (2014) 0.85
Sustained wound healing activity of curcumin loaded oleic acid based polymeric bandage in a rat model. Mol Pharm (2012) 0.85
Codelivery of DNA and siRNA via arginine-rich PEI-based polyplexes. Mol Pharm (2015) 0.84
Nanoparticle-mediated p53 gene therapy for tumor inhibition. Drug Deliv Transl Res (2011) 0.84
Selective biophysical interactions of surface modified nanoparticles with cancer cell lipids improve tumor targeting and gene therapy. Cancer Lett (2013) 0.83
Encapsulation in nanoparticles improves anti-cancer efficacy of carboplatin. AAPS PharmSciTech (2014) 0.82
Targeted therapy of cancer using diphtheria toxin-derived immunotoxins. Drug Discov Today (2008) 0.82
In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer. J Med Chem (2014) 0.82
Etoposide-loaded biodegradable amphiphilic methoxy (poly ethylene glycol) and poly (epsilon caprolactone) copolymeric micelles as drug delivery vehicle for cancer therapy. Drug Deliv (2010) 0.81
Nanoparticles for delivery of chemotherapeutic agents to tumors. Curr Opin Investig Drugs (2007) 0.81
Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. PLoS One (2013) 0.81
Optical imaging to map blood-brain barrier leakage. Sci Rep (2013) 0.81
Erythropoietin induces excessive neointima formation: a study in a rat carotid artery model of vascular injury. J Cardiovasc Pharmacol Ther (2007) 0.80
Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neurons. AIDS Res Hum Retroviruses (2011) 0.80
Nanoparticles for imaging, diagnosis, and therapeutics. Mol Pharm (2009) 0.80
Biomechanics and thermodynamics of nanoparticle interactions with plasma and endosomal membrane lipids in cellular uptake and endosomal escape. Langmuir (2014) 0.80
Retracted Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy. Acta Biomater (2010) 0.79
Emerging role of nanocarriers to increase the solubility and bioavailability of curcumin. Expert Opin Drug Deliv (2012) 0.79
Retracted Antiglioma activity of curcumin-loaded lipid nanoparticles and its enhanced bioavailability in brain tissue for effective glioblastoma therapy. Acta Biomater (2012) 0.79
Preparation of biodegradable nanoparticles and their use in transfection. CSH Protoc (2008) 0.79
Sustained targeting of Bcr-Abl + leukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy. Biomaterials (2011) 0.78
Heterogeneity in nanoparticles influences biodistribution and targeting. Nanomedicine (Lond) (2013) 0.78
Drug Resistant Breast Cancer Cell Line Displays Cancer Stem Cell Phenotype and Responds Sensitively to Epigenetic Drug SAHA. Drug Deliv Transl Res (2012) 0.77
A novel approach for cancer immunotherapy: tumor cells with anchored superantigen SEA generate effective antitumor immunity. J Clin Immunol (2004) 0.76